Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data June 18, 2015 10:03 AM BioMarin's (BMRN) Price Target Raised to $156 at Deutsche BankJune 18, 2015 8:19 AM BioMarin (BMRN) PT Lifted to 'Street High' $170 at SunTrust Amid Growing Confidence in Dwarfism Drug BMN 111June 18, 2015 7:51 AM BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC June 18, 2015 7:35 AM BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 UpdateJune 18, 2015 7:02 AM BioMarin Pharma (BMRN) Issues Positive Update from BMN 111 Phase 2 Proof-of-Concept, Dose Finding StudyJune 17, 2015 4:05 PM BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 StudyJune 17, 2015 4:01 PM